Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 3/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.44 |
| ▸ | NPC1 | O15118 | 2/20 | 0.44 |
| ▸ | RAB9A | P51151 | 2/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.43 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.43 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.42 |
| ▸ | TSHR | P16473 | 1/20 | 0.42 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.42 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
| ▸ | RECQL | P46063 | 1/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | GPR35 | Q9HC97 | 1/20 | 0.39 |
| ▸ | RBP4 | P02753 | 1/20 | 0.38 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.38 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.38 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.38 |
| ▸ | POLB | P06746 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2713871 | 0.81 | CYP1A2 (0.58) | MAPTSMN1; SMN2NPC1RAB9AKMT2A | |
| SCHEMBL1180020 | 0.80 | KMT2A (0.51) | MAPTSMN1; SMN2NPC1RAB9AKMT2A | |
| SCHEMBL1180045 | 0.80 | MAPK1 (0.47) | MAPTSMN1; SMN2NPC1RAB9AKMT2A | |
| SCHEMBL2714755 | 0.78 | ADORA1 (0.51) | MAPTSMN1; SMN2NPC1RAB9AKMT2A | |
| SCHEMBL1178661 | 0.78 | KDM4E (0.57) | MAPTSMN1; SMN2NPC1RAB9AKMT2A | |
| SCHEMBL1178837 | 0.78 | MCHR1 (0.45) | KDM4E | |
| SCHEMBL2715069 | 0.78 | TSHR (0.55) | MAPTSMN1; SMN2KMT2AKDM4EALDH1A1 | |
| SCHEMBL1425523 | 0.77 | ALOX15 (0.42) | MAPTSMN1; SMN2NPC1RAB9AKMT2A | |
| SCHEMBL1179629 | 0.77 | HCAR2 (0.39) | NPC1RAB9AKMT2AKDM4EALDH1A1 | |
| SCHEMBL1178977 | 0.76 | ESR1 (0.49) | MAPTSMN1; SMN2NPC1RAB9AKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1888579-B1 | NOVEL FLUORENE DERIVATIVES, COMPOSITION CONTAINING SAID DERIVATIVES AND THE USE THEREOF | AVENTIS PHARMA SA (FR) | 2011-08-03 | — | — | EP | claimed |
| US-7674795-B2 | Fluorene derivatives, composition containing said derivatives and the use thereof | AVENTIS PHARMA SA (FR) | 2010-03-09 | — | — | US | claimed |
| US-20080153837-A1 | Novel Fluorene Derivatives, Composition Containing Said Derivatives and the Use Thereof | AVENTIS PHARMA S.A. (FR) | 2008-06-26 | — | — | US | claimed |
| EP-2217594-B1 | NOVEL PYRIMIDINE DERIVATIVES | ACTELION PHARMACEUTICALS LTD (CH) | 2014-01-08 | — | — | EP | disclosed |
| CN-101203518-B | Fluorene derivative, composition containing the same and use thereof | AVENTIS PHARMA SA | 2013-07-24 | — | — | CN | disclosed |
| CN-101970430-B | Novel pyrimidine derivatives | ACTELION PHARMACEUTICALS LTD | 2013-05-08 | — | — | CN | disclosed |
| US-8299086-B2 | Pyrimidine derivatives | ACTELION PHARMACEUTICALS LTD. (CH) | 2012-10-30 | — | — | US | disclosed |
| US-20110046170-A1 | NOVEL PYRIMIDINE-PYRIDINE DERIVATIVES | ACTELION PHARMACEUTICALS LTD. (CH) | 2011-02-24 | — | — | US | disclosed |
| CN-101970430-A | Novel pyrimidine derivatives | ACTELION PHARMACEUTICALS LTD | 2011-02-09 | — | — | CN | disclosed |
| CN-101965346-A | Novel pyrimidine-pyridine derivatives | ACTELION PHARMACEUTICALS LTD | 2011-02-02 | — | — | CN | disclosed |
| US-20100234346-A1 | NOVEL PYRIMIDINE DERIVATIVES | ACTELION PHARMACEUTICALS LTD. (CH) | 2010-09-16 | — | — | US | disclosed |
| EP-2217594-A2 | NOVEL PYRIMIDINE DERIVATIVES | Actelion Pharmaceuticals Ltd. (CH) | 2010-08-18 | — | — | EP | disclosed |
| US-7674795-B2 | Fluorene derivatives, composition containing said derivatives and the use thereof | AVENTIS PHARMA SA (FR) | 2010-03-09 | — | — | US | disclosed |
| WO-2009057079-A2 | NOVEL PYRIMIDINE DERIVATIVES | ACTELION PHARMACEUTICALS LTD (CH) | 2009-05-07 | — | — | WO | disclosed |
| US-20080153837-A1 | Novel Fluorene Derivatives, Composition Containing Said Derivatives and the Use Thereof | AVENTIS PHARMA S.A. (FR) | 2008-06-26 | — | — | US | disclosed |
| CN-101203518-A | Novel fluorene derivatives, compositions containing same and uses thereof | AVENTIS PHARMA SA (FR) | 2008-06-18 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100234346-A1 | NOVEL PYRIMIDINE DERIVATIVES | TYMP, TYMS, DPYD | MAPT 3934/4885SMN1; SMN2 4171/4885NPC1 2818/4885 |
| US-20110046170-A1 | NOVEL PYRIMIDINE-PYRIDINE DERIVATIVES | TYMP, DPYD, ENTPD5 | MAPT 3786/4885SMN1; SMN2 4245/4885NPC1 3223/4885 |
| US-20080153837-A1 | Novel Fluorene Derivatives, Composition Containing Said Derivatives and the Use Thereof | HSP90B1, HSP90AB1, HSP90AA1 | MAPT 844/4885SMN1; SMN2 1564/4885NPC1 245/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.